GlaxoSmithKline (GSK) and Merck KGaA announced that results from the recently completed vilazodone Phase IIB program in depression are now available. Based on these results, the data do not support progression to Phase III trials and GSK will return all rights to vilazodone to Merck, under the terms of the agreement. Merck is currently evaluating further options with respect to this compound.
Vilazodone, also known as EMD 68843 or SB 659746-A, was discovered and transferred into early clinical development by Merck. It combines the properties of a selective serotonin-reuptake inhibitor (SSRI) with that of a 5-HT1A partial agonist.